Atacicept is a novel immunomodulatory therapy that inhibits BLyS and APRIL signaling, which has been shown to reduce Ig levels in patients with autoimmune diseases, including systemic lupus erythematosus.21 Here, TNFSF13 is linked to autoimmune disease.